All In Biotech

Drug Trial Radar · NCT03523585

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 608 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

608

Actual

Start

Aug 1, 2018

Primary completion

Jun 30, 2022

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Daiichi Sankyo Co., Ltd.; AstraZeneca
First posted
May 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before. Their cancer: * cannot be removed by an operation * has spread to other parts of the body

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab deruxtecanDrug

    DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose

  • CapecitabineDrug

    Investigator's choice Standard of Care when combined with trastuzumab or lapatinib

  • LapatinibDrug

    Investigator's choice Standard of Care when combined with capecitabine

  • TrastuzumabDrug

    Investigator's choice Standard of Care when combined with capecitabine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab EmtansineTime frame: Baseline up to 46 months postdose

Locations

227 sites in 15 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer Research Centers

    Chandler, Arizona

  • UCLA Hematology Oncology - Main Site

    Los Angeles, California

  • Pacific Cancer Care

    Monterey, California

  • Sharp Memorial Hospital

    San Diego, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Washington Cancer Institute

    Washington D.C., District of Columbia

  • Florida Cancer Specialists-Broadway

    Fort Myers, Florida

  • Piedmont Cancer Institute, PC

    Atlanta, Georgia

  • Kapiolani Medical Center for Women and Children/Univ of HI

    Honolulu, Hawaii

  • Loyola University Health System

    Maywood, Illinois

  • Community Hospital

    Munster, Indiana

  • Norton Cancer Institute

    Louisville, Kentucky

  • Maine Center for Cancer Medicine

    Scarborough, Maine

  • University of Maryland

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Cornell-Beshore Cancer Institute

    Joplin, Missouri

  • Saint Luke's Cancer Institute

    Kansas City, Missouri

  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC

    Kansas City, Missouri

  • Washington University

    St Louis, Missouri

  • North Shore Hematology Oncology Associates, PC

    East Setauket, New York

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Main Campus

    Cleveland, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Dayton Physicians, LLC

    Kettering, Ohio

  • Abramson Cancer Center

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • Tennessee Oncology, PLLC Chattanooga

    Chattanooga, Tennessee

  • The West Clinic

    Germantown, Tennessee

  • SCRI - Tennessee Oncology

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • The Methodist Hospital Research Institute

    Houston, Texas

  • The University of Texas Health Science Center at Tyler

    Tyler, Texas

  • Community Cancer Trials of Utah

    Ogden, Utah

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

Showing 40 of 227 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.